Tarsitano Christiane Aparecida Badin, Paffaro Valdemar A, Pauli José Rodrigo, da Silva Gustavo Henrique, Saad Mario J, Salgado Ione, da Cruz-Höfling Maria Alice, Hyslop Stephen
Departamento de Farmacologia, Faculdade de Ciências Médicas, Universidade Estadual de Campinas (UNICAMP), CP 6111, 13083-970 Campinas, SP, Brazil.
Cell Tissue Res. 2007 Jul;329(1):45-58. doi: 10.1007/s00441-007-0411-9. Epub 2007 Apr 14.
Chronic treatment of rats with N(omega)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide (NO) biosynthesis, results in hypertension mediated partly by enhanced angiotensin-I-converting enzyme (ACE) activity. We examined the influence of L-NAME on rat liver morphology, on hepatic glycogen, cholesterol, and triglyceride content, and on the activities of the cytochrome P450 isoforms CYP1A1/2, CYP2B1/2, CYP2C11, and CYP2E1. Male Wistar rats were treated with L-NAME (20 mg/rat per day via drinking water) for 2, 4, and 8 weeks, and their livers were then removed for analysis. Enzymatic induction was produced by treating rats with phenobarbital (to induce CYP2B1/2), beta-naphthoflavone (to induce CYP1A1/2), or pyrazole (to induce CYP2E1). L-NAME significantly elevated blood pressure; this was reversed by concomitant treatment with enalapril (ACE inhibitor) or losartan (angiotensin II AT(1) receptor antagonist). L-NAME caused vascular hypertrophy in hepatic arteries, with perivascular and interstitial fibrosis involving collagen deposition. Hepatic glycogen content also significantly increased. L-NAME did not affect fasting glucose levels but significantly reduced insulin levels and increased the insulin sensitivity of rats, based on an intraperitoneal glucose tolerance test. Immunoblotting experiments indicated enhanced phosphorylation of protein kinase B and of glycogen synthase kinase 3. All these changes were reversed by concomitant treatment with enalapril or losartan. L-NAME had no effect on hepatic cholesterol or triglyceride content or on the basal or drug-induced activities and protein expression of the cytochrome P450 isoforms. Thus, the chronic inhibition of NO biosynthesis produced hepatic morphological alterations and changes in glycogen metabolism mediated by the renin-angiotensin system. The increase in hepatic glycogen content probably resulted from enhanced glycogen synthase activity following the inhibition of glycogen synthase kinase 3 by phosphorylation.
用一氧化氮(NO)生物合成抑制剂N(ω)-硝基-L-精氨酸甲酯(L-NAME)对大鼠进行长期治疗,会导致高血压,部分原因是血管紧张素-I转换酶(ACE)活性增强。我们研究了L-NAME对大鼠肝脏形态、肝糖原、胆固醇和甘油三酯含量以及细胞色素P450同工酶CYP1A1/2、CYP2B1/2、CYP2C11和CYP2E1活性的影响。雄性Wistar大鼠经L-NAME(每天20 mg/只,通过饮用水给药)处理2、4和8周,然后取出肝脏进行分析。用苯巴比妥(诱导CYP2B1/2)、β-萘黄酮(诱导CYP1A1/2)或吡唑(诱导CYP2E1)处理大鼠以产生酶诱导作用。L-NAME显著升高血压;用依那普利(ACE抑制剂)或氯沙坦(血管紧张素II AT(1)受体拮抗剂)联合治疗可使其逆转。L-NAME导致肝动脉血管肥大,伴有血管周围和间质纤维化,涉及胶原沉积。肝糖原含量也显著增加。基于腹腔内葡萄糖耐量试验,L-NAME不影响空腹血糖水平,但显著降低胰岛素水平并增加大鼠的胰岛素敏感性。免疫印迹实验表明蛋白激酶B和糖原合酶激酶3的磷酸化增强。所有这些变化都可通过依那普利或氯沙坦联合治疗逆转。L-NAME对肝脏胆固醇或甘油三酯含量以及细胞色素P450同工酶的基础或药物诱导活性及蛋白表达均无影响。因此,长期抑制NO生物合成会导致肝脏形态改变以及由肾素-血管紧张素系统介导的糖原代谢变化。肝糖原含量增加可能是由于糖原合酶激酶3被磷酸化抑制后糖原合酶活性增强所致。